These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18609486)

  • 21. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visual field defects with vigabatrin: epidemiology and therapeutic implications.
    Kälviäinen R; Nousiainen I
    CNS Drugs; 2001; 15(3):217-30. PubMed ID: 11463129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
    Wild JM; Robson CR; Jones AL; Cunliffe IA; Smith PE
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):917-24. PubMed ID: 16505024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
    Riise P; Fledelius HC; Rogvi-Hansen Bà
    Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of a unique visual field defect attributed to vigabatrin.
    Wild JM; Martinez C; Reinshagen G; Harding GF
    Epilepsia; 1999 Dec; 40(12):1784-94. PubMed ID: 10612345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.
    Krauss GL; Johnson MA; Sheth S; Miller NR
    J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):339-43. PubMed ID: 12588920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual field loss associated with vigabatrin: quantification and relation to dosage.
    Hardus P; Verduin WM; Engelsman M; Edelbroek PM; Segers JP; Berendschot TT; Stilma JS
    Epilepsia; 2001 Feb; 42(2):262-7. PubMed ID: 11240600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
    Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V
    Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
    Sorri I
    Acta Ophthalmol Scand; 2002 Jun; 80(3):343-4. PubMed ID: 12059879
    [No Abstract]   [Full Text] [Related]  

  • 33. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
    Hisama FM; Mattson RH; Lee HH; Felice K; Petroff OA
    Seizure; 2001 Oct; 10(7):505-7. PubMed ID: 11749107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinal function abnormalities in patients treated with vigabatrin.
    Banin E; Shalev RS; Obolensky A; Neis R; Chowers I; Gross-Tsur V
    Arch Ophthalmol; 2003 Jun; 121(6):811-6. PubMed ID: 12796251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual defects associated with vigabatrin: a study of epileptic argentine patients.
    Moreno MC; Giagante B; Saidon P; Kochen S; Benozzi J; Rosenstein RE
    Can J Neurol Sci; 2005 Nov; 32(4):459-64. PubMed ID: 16408575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients treated with vigabatrin exhibit central visual function loss.
    Hilton EJ; Cubbidge RP; Hosking SL; Betts T; Comaish IF
    Epilepsia; 2002 Nov; 43(11):1351-9. PubMed ID: 12423385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.
    Kälviäinen R; Nousiainen I; Mäntyjärvi M; Nikoskelainen E; Partanen J; Partanen K; Riekkinen P
    Neurology; 1999 Sep; 53(5):922-6. PubMed ID: 10496247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study.
    Schmitz B; Schmidt T; Jokiel B; Pfeiffer S; Tiel-Wilck K; Rüther K
    J Neurol; 2002 Apr; 249(4):469-75. PubMed ID: 11967655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visual field defects in pediatric patients on vigabatrin monotherapy.
    Ascaso FJ; Lopez MJ; Mauri JA; Cristobal JA
    Doc Ophthalmol; 2003 Sep; 107(2):127-30. PubMed ID: 14661902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.